Abstract
Cytokine-based therapeutic approaches using interferon (IFN) and interleukin 2 (IL-2) were conventionally applied for the treatment of progressive RCC. Caused by the limited effectiveness of cytokine-based approaches in advanced renal cell carcinoma, new substances were needed. Among these, the “targeted therapies”, particularly the group of the tyrosine kinase inhibitors, are of main interest. At present, multikinase inhibitors and antiangiogenic agents (VEGFR, PDGFR-beta, and mTOR) are used in first- and second-line therapies of metastatic RCC in various clinical studies. This review presents and discusses the effectiveness of the most frequently used substances in mono- or combination regimes based on current data of the ASCO 2007.
Keywords: Renal cell carcinoma, tyrosine kinase inhibitor, antiangiogenic agents, ASCO 2007, combination regime, targeted therapies
Reviews on Recent Clinical Trials
Title: Novel Therapeutic Options in Metastatic Renal Cancer – Review and Post ASCO 2007 Update
Volume: 3 Issue: 3
Author(s): Stephan Kruck, Markus A. Kuczyk, Georgios Gakis, Mario W. Kramer, Arnulf Stenzl and Axel S. Merseburger
Affiliation:
Keywords: Renal cell carcinoma, tyrosine kinase inhibitor, antiangiogenic agents, ASCO 2007, combination regime, targeted therapies
Abstract: Cytokine-based therapeutic approaches using interferon (IFN) and interleukin 2 (IL-2) were conventionally applied for the treatment of progressive RCC. Caused by the limited effectiveness of cytokine-based approaches in advanced renal cell carcinoma, new substances were needed. Among these, the “targeted therapies”, particularly the group of the tyrosine kinase inhibitors, are of main interest. At present, multikinase inhibitors and antiangiogenic agents (VEGFR, PDGFR-beta, and mTOR) are used in first- and second-line therapies of metastatic RCC in various clinical studies. This review presents and discusses the effectiveness of the most frequently used substances in mono- or combination regimes based on current data of the ASCO 2007.
Export Options
About this article
Cite this article as:
Kruck Stephan, Kuczyk A. Markus, Gakis Georgios, Kramer W. Mario, Stenzl Arnulf and Merseburger S. Axel, Novel Therapeutic Options in Metastatic Renal Cancer – Review and Post ASCO 2007 Update, Reviews on Recent Clinical Trials 2008; 3 (3) . https://dx.doi.org/10.2174/157488708785700311
DOI https://dx.doi.org/10.2174/157488708785700311 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Folic Acid Conjugated Chitosan Nanoparticles for Tumor Targeting of Therapeutic and Imaging Agents
Pharmaceutical Nanotechnology Editorial [Hot Topic: Lipids in Cancer Cell Biology and Therapy Guest Editor: Jose C. Fernandez-Checa)]
Anti-Cancer Agents in Medicinal Chemistry Biological and Pharmacological Roles of N6-Isopentenyladenosine: An Emerging Anticancer Drug
Anti-Cancer Agents in Medicinal Chemistry Single-Photon Emission Computed Tomography Tracers for Predicting and Monitoring Cancer Therapy
Current Pharmaceutical Biotechnology Computational Insights into the Role of Glutathione in Oxidative Stress
Current Neurovascular Research Prophylactic Vaccine Approach for Colon and Pancreatic Cancers: Present and Future
Current Medicinal Chemistry Targeting Cancer Stem Cells as a Therapeutic Approach in Liver Cancer
Current Gene Therapy <i>In Vivo</i> Antitumor, Pharmacological and Toxicological Study of Pyrimido[ 4′,5′:4,5] thieno(2,3-b)quinoline with 9-hydroxy-4-(3-diethylaminopropylamino) and 8-methoxy-4-(3-diethylaminopropylamino) Substitutions
Anti-Cancer Agents in Medicinal Chemistry Current Status of Delivery Systems to Improve Target Efficacy of Oligonu-cleotides
Current Pharmaceutical Design Phosphoinositide 3-Kinases and Leukocyte Migration
Current Immunology Reviews (Discontinued) PET Imaging to Monitor Cancer Therapy
Current Pharmaceutical Biotechnology A Brief Evaluation of Tumor Imaging in Mice with 99mTc-glucarate Including a Comparison with 18F-FDG
Current Radiopharmaceuticals ABC Transporters in the Development of Multidrug Resistance in Cancer Therapy
Current Pharmaceutical Design Gynecomastia in Infants, Children, and Adolescents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Thalidomide Metabolism and Hydrolysis: Mechanisms and Implications
Current Drug Metabolism The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory
Current Pharmaceutical Design Comprehensive Review of Cancer Chemopreventive Agents Evaluated in Experimental Carcinogenesis Models and Clinical Trials
Current Medicinal Chemistry Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases
Current Topics in Medicinal Chemistry Antiangiogenic Therapeutic Approaches in Multiple Myeloma
Current Cancer Drug Targets The Anti-cancer Actions of Vitamin D
Anti-Cancer Agents in Medicinal Chemistry